- Conditions
- Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
- Interventions
- Talimogene laherparepvec, Paclitaxel
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 138
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
- Interventions
- Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
- Conditions
- Perimenopause-Related Depression
- Interventions
- Estradiol, ER Beta Agonist, Placebo, Provera
- Drug · Other
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Neoplasms
- Interventions
- THERATOPE® vaccine
- Drug
- Lead sponsor
- Oncothyreon Canada Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 17
- States / cities
- Berkeley, California • San Francisco, California • Santa Monica, California + 14 more
- Conditions
- Cystic Fibrosis, Hypoestrogenism
- Interventions
- Transdermal estrogen, Progesterone
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 0 Years to 100 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leiomyoma
- Interventions
- ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Anorexia Nervosa
- Interventions
- Physiologic Estrogen/progesterone, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Prevention
- Interventions
- Estrogen, Estrogen plus Progesterone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Covid19
- Interventions
- Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
- Other · Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Depression, Psychosis, Anhedonia
- Interventions
- Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer, Stage IV Breast Cancer
- Interventions
- tamoxifen
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more
- Conditions
- Breast Cancer
- Interventions
- PF-07248144, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 215
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 365
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
- Conditions
- Breast Cancer
- Interventions
- exemestane, tamoxifen, triptorelin
- Drug
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Network
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2,672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 139
- States / cities
- Burbank, California • La Jolla, California • Mission Hills, California + 106 more
- Conditions
- Turner Syndrome, Hypogonadism, Premature Ovarian Failure
- Interventions
- 17 B estradiol orally, 17 B estradiol
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 20 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 539
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
- Conditions
- Anorexia Nervosa
- Interventions
- RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 22 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- ZARNESTRA, tipifarnib, R115777
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 6
- States / cities
- Miami, Florida • Chicago, Illinois • Durham, North Carolina + 3 more
- Conditions
- Hypertension, Menopause, Premature, Menopause, Blood Pressure
- Interventions
- Microneurography to measure muscle sympathetic nerve activity (MSNA), Baroreflex sensitivity testing, Sympathoexcitatory Maneuvers, Blood tests
- Diagnostic Test
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 35 Years to 70 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Women's Health
- Interventions
- Resistance Training
- Behavioral
- Lead sponsor
- Southern Illinois University Edwardsville
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Edwardsville, Illinois
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Adjuvant endocrine therapy, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
- Conditions
- Suicidal Ideation
- Interventions
- Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Amenorrhea, Bone Loss
- Interventions
- Estrogen
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 21 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
- Genetic · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Female only
- Enrollment
- 957 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts